<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d495" origId="Levobunolol"><sentence id="DrugDDI.d495.s0" origId="s0" text="Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur."><entity charOffset="9-16" id="DrugDDI.d495.s0.e0" origId="s0.p1" text="BETAGAN" type="drug"/><entity charOffset="117-124" id="DrugDDI.d495.s0.e1" origId="s0.p12" text="BETAGAN" type="drug"/><entity charOffset="129-140" id="DrugDDI.d495.s0.e2" origId="s0.p14" text="epinephrine" type="drug"/><pair e1="DrugDDI.d495.s0.e0" e2="DrugDDI.d495.s0.e1" id="DrugDDI.d495.s0.p0" interaction="false"/><pair e1="DrugDDI.d495.s0.e0" e2="DrugDDI.d495.s0.e2" id="DrugDDI.d495.s0.p1" interaction="false"/><pair e1="DrugDDI.d495.s0.e1" e2="DrugDDI.d495.s0.e2" id="DrugDDI.d495.s0.p2" interaction="false"/><negationtags>Although BETAGAN used alone has little or &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; effect on pupil size&lt;/xcope&gt;, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.</negationtags></sentence><sentence id="DrugDDI.d495.s1" origId="s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension."><entity charOffset="55-67" id="DrugDDI.d495.s1.e0" origId="s1.p22" text="beta-blocker" type="drug"/><entity charOffset="130-135" id="DrugDDI.d495.s1.e1" origId="s1.p27" text="drugs" type="drug"/><entity charOffset="144-153" id="DrugDDI.d495.s1.e2" origId="s1.p28" text="reserpine" type="drug"/><pair e1="DrugDDI.d495.s1.e0" e2="DrugDDI.d495.s1.e1" id="DrugDDI.d495.s1.p0" interaction="true"/><pair e1="DrugDDI.d495.s1.e0" e2="DrugDDI.d495.s1.e2" id="DrugDDI.d495.s1.p1" interaction="false"/><pair e1="DrugDDI.d495.s1.e1" e2="DrugDDI.d495.s1.e2" id="DrugDDI.d495.s1.p2" interaction="false"/></sentence><sentence id="DrugDDI.d495.s2" origId="s2" text="Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension."><entity charOffset="19-50" id="DrugDDI.d495.s2.e0" origId="s2.p44" text="beta-adrenergic blocking agents" type="drug"/><entity charOffset="89-107" id="DrugDDI.d495.s2.e1" origId="s2.p50" text="calcium antagonist" type="drug"/><pair e1="DrugDDI.d495.s2.e0" e2="DrugDDI.d495.s2.e1" id="DrugDDI.d495.s2.p0" interaction="true"/><negationtags>Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular &lt;xcope&gt;&lt;cue&gt;failure&lt;/cue&gt; and hypotension&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d495.s3" origId="s3" text="In patients with impaired cardiac function, simultaneous use should be avoided altogether."/><sentence id="DrugDDI.d495.s4" origId="s4" text="The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time."><entity charOffset="23-54" id="DrugDDI.d495.s4.e0" origId="s4.p66" text="beta-adrenergic blocking agents" type="drug"/><entity charOffset="60-69" id="DrugDDI.d495.s4.e1" origId="s4.p67" text="digitalis" type="drug"/><entity charOffset="74-92" id="DrugDDI.d495.s4.e2" origId="s4.p69" text="calcium antagonist" type="drug"/><pair e1="DrugDDI.d495.s4.e0" e2="DrugDDI.d495.s4.e1" id="DrugDDI.d495.s4.p0" interaction="true"/><pair e1="DrugDDI.d495.s4.e0" e2="DrugDDI.d495.s4.e2" id="DrugDDI.d495.s4.p1" interaction="false"/><pair e1="DrugDDI.d495.s4.e1" e2="DrugDDI.d495.s4.e2" id="DrugDDI.d495.s4.p2" interaction="false"/></sentence><sentence id="DrugDDI.d495.s5" origId="s5" text="Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other?s metabolism."><entity charOffset="0-13" id="DrugDDI.d495.s5.e0" origId="s5.p74" text="Phenothiazine" type="drug"/><entity charOffset="36-67" id="DrugDDI.d495.s5.e1" origId="s5.p76" text="beta-adrenergic blocking agents" type="drug"/><pair e1="DrugDDI.d495.s5.e0" e2="DrugDDI.d495.s5.e1" id="DrugDDI.d495.s5.p0" interaction="true"/></sentence></document>